Market expansion Avinger is expanding from PAD-focused therapies to coronary artery disease CAD applications, signaling cross-market opportunities for intravascular image-guided systems in CTO crossing and potential upsell of the Lightbox console and Pantheris/OCelot family.

Public funding momentum Recent public fundraising activity and a disclosed 6 million raise post-IPO indicate investor appetite and financial runway to pursue aggressive product development and market entry efforts, suggesting readiness for partner-led sales initiatives and early adopter programs.

Product pipeline New Tigereye ST CTO crossing device and image-guided CAD application expand the product portfolio, offering multiple entry points for hospitals to adopt image-guided atherectomy and CTO crossing solutions, facilitating multi-product deals.

Clinical adoption Limited release at top U.S. clinical centers demonstrates early clinical validation and potential for reference sites, enabling a focused sales strategy around center-of-excellence accounts and clinician-led recommendations.

Strategic fit Alignment with major medical device ecosystems (WordPress, Salesforce, SAP, CRM and data-integrated workflows) plus a relatively lean team presents an opportunity to partner with large distributors and systems integrators to scale sales and service capabilities.